{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:41:54Z","timestamp":1777329714938,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T00:00:00Z","timestamp":1495843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s10198-017-0903-9","type":"journal-article","created":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T13:54:22Z","timestamp":1495893262000},"page":"571-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Introduction of therapeutic reference pricing in Slovenia and its economic consequences"],"prefix":"10.1007","volume":"19","author":[{"given":"Nika","family":"Mar\u0111etko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitja","family":"Kos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,27]]},"reference":[{"issue":"1","key":"903_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2191-1991-1-18","volume":"1","author":"F Schulenburg von der","year":"2011","unstructured":"von der Schulenburg, F., Vandoros, S., Kanavos, P.: The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Econ. Rev. 1(1), 18 (2011). doi:\n                        10.1186\/2191-1991-1-18","journal-title":"Health Econ. Rev."},{"issue":"1","key":"903_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/11537860-000000000-00000","volume":"29","author":"MM Galizzi","year":"2011","unstructured":"Galizzi, M.M., Ghislandi, S., Miraldo, M.: Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics 29(1), 17\u201333 (2011). doi:\n                        10.2165\/11537860-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"903_CR3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00019053-200321020-00002","volume":"21","author":"SM Ess","year":"2003","unstructured":"Ess, S.M., Schneeweiss, S., Szucs, T.D.: European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21(2), 89\u2013103 (2003)","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"903_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1586\/erp.12.66","volume":"12","author":"C Usher","year":"2012","unstructured":"Usher, C., Barry, M.: A reference pricing system for Ireland. Expert Rev. Pharm. Out. Res. 12(6), 675\u2013677 (2012). doi:\n                        10.1586\/erp.12.66","journal-title":"Expert Rev. Pharm. Out. Res."},{"key":"903_CR5","unstructured":"Health Insurance Institute of Slovenia: Therapeutic reference pricing system in Slovenia\u2014explanation for the insured population [in Slovenian]. \n                        http:\/\/www.zzzs.si\/zzzs\/internet\/zzzs.nsf\/o\/6A6BD0CD7CB327B3C1257BD900451900?OpenDocument\n                        \n                     (2013). Accessed 5 June 2016"},{"key":"903_CR6","unstructured":"Forum of International Research and Development Pharmaceutical Companies EIG: Health insurance institute of Slovenia has introduced the first therapeutic class of medicines [in Slovenian]. \n                        http:\/\/firdpc.com\/sl\/Aktualno\/ZZZS_uvaja_prvo_terapevtsko_skupino_zdravil_dopolnjeno\/\n                        \n                     (2013). Accessed 26 Nov 2016"},{"issue":"1","key":"903_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1370\/afm.1484","volume":"11","author":"LS Wallace","year":"2013","unstructured":"Wallace, L.S.: A view of health care around the world. Ann. Fam. Med. 11(1), 84 (2013). doi:\n                        10.1370\/afm.1484","journal-title":"Ann. Fam. Med."},{"key":"903_CR8","unstructured":"A World Health Organization: Essential medicines and health products information portal, experiences with reference pricing. \n                        http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js4912e\/3.3.html\n                        \n                     (2003). Accessed 20 Oct 2016"},{"key":"903_CR9","unstructured":"Forum of International Research and Development Pharmaceutical Companies EIG: Opinion on therapeutic reference pricing [in Slovenian]. \n                        http:\/\/www.firdpc.com\/sl\/Sodelovanje_z_delezniki\/\n                        \n                     (2014). Accessed 26 Nov 2016"},{"key":"903_CR10","unstructured":"Forum of International Research and Development Pharmaceutical Companies EIG: Therapeutic reference pricing is harmful to patients [in Slovenian]. \n                        http:\/\/www.firdpc.com\/sl\/Dogodki_in_novice\/Terapevtske_skupine_zdravil\/\n                        \n                     (2013). Accessed 26 Nov 2016"},{"key":"903_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2466-12-35","volume":"12","author":"Z Kalo","year":"2012","unstructured":"Kalo, Z., Abonyi-Toth, Z., Bartfai, Z., Voko, Z.: Pitfalls associated with the therapeutic reference pricing practice of asthma medication. BMC Pulm. Med. 12, 35 (2012). doi:\n                        10.1186\/1471-2466-12-35","journal-title":"BMC Pulm. Med."},{"key":"903_CR12","unstructured":"Health Insurance Institute of Slovenia: [Introduction of the therapeutic reference pricing into Slovenian health care system\u2014explanation for the insured population] Uvedba sistema najvi\u0161jih priznanih vrednosti za terapevtske skupine zdravil\u2014pojasnilo za zavarovane osebe [In Slovenian]. \n                        http:\/\/www.zzzs.si\/zzzs\/internet\/zzzs.nsf\/o\/6A6BD0CD7CB327B3C1257BD900451900?OpenDocument\n                        \n                     (2013). Accessed 4 Mar 2016"},{"issue":"3","key":"903_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jhealeco.2006.11.003","volume":"26","author":"KR Brekke","year":"2007","unstructured":"Brekke, K.R., Konigbauer, I., Straume, O.R.: Reference pricing of pharmaceuticals. J. Health Econ. 26(3), 613\u2013642 (2007). doi:\n                        10.1016\/j.jhealeco.2006.11.003","journal-title":"J. Health Econ."},{"issue":"3","key":"903_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.healthpol.2006.04.002","volume":"80","author":"Z Kalo","year":"2007","unstructured":"Kalo, Z., Muszbek, N., Bodrogi, J., Bidlo, J.: Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 80(3), 402\u2013412 (2007). doi:\n                        10.1016\/j.healthpol.2006.04.002","journal-title":"Health Policy"},{"key":"903_CR15","unstructured":"Organisation for Economic Co-operation and Development (OECD): Pharmaceutical pricing policies in a global market. \n                        http:\/\/apps.who.int\/medicinedocs\/documents\/s19834en\/s19834en.pdf\n                        \n                     (2008). Accessed 20 Oct 2016"},{"issue":"6","key":"903_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/erp.11.70","volume":"11","author":"P Dylst","year":"2011","unstructured":"Dylst, P., Vulto, A., Simoens, S.: The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev. Pharm. Out. Res. 11(6), 729\u2013737 (2011). doi:\n                        10.1586\/erp.11.70","journal-title":"Expert Rev. Pharm. Out. Res."},{"key":"903_CR17","unstructured":"Online Database of Medicinal Products in Slovenia. \n                        http:\/\/www.cbz.si\/cbz\/bazazdr2.nsf\/Search\/$searchForm?SearchView\n                        \n                     (2016). Accessed 10 Aug 2016"},{"issue":"4","key":"903_CR18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner, A.K., Soumerai, S.B., Zhang, F., Ross-Degnan, D.: Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27(4), 299\u2013309 (2002)","journal-title":"J. Clin. Pharm. Ther."},{"key":"903_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1475-9276-13-53","volume":"13","author":"C Leopold","year":"2014","unstructured":"Leopold, C., Zhang, F., Mantel-Teeuwisse, A.K., Vogler, S., Valkova, S., Ross-Degnan, D., Wagner, A.K.: Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. Int. J. Equity Health 13, 53 (2014). doi:\n                        10.1186\/1475-9276-13-53","journal-title":"Int. J. Equity Health"},{"key":"903_CR20","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: Definition and general considerations. \n                        http:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/\n                        \n                     (2016). Accessed 9 Aug 2016"},{"key":"903_CR21","unstructured":"Statistical Office of the Republic of Slovenia: Population number and structure. \n                        http:\/\/www.stat.si\/StatWeb\/en\/home\n                        \n                     (2016). Accessed 9 Aug 2016"},{"key":"903_CR22","unstructured":"Frakt, A.: The incidental economist. The health services research blog. Market concentration and entry. \n                        http:\/\/theincidentaleconomist.com\/wordpress\/market-concentration-and-entry\/\n                        \n                    . Accessed 16 Aug 2016"},{"key":"903_CR23","unstructured":"Investopedia: Herfindahl\u2013Hirschman Index\u2014HHI. \n                        http:\/\/www.investopedia.com\/terms\/h\/hhi.asp#ixzz4H0ZEoISh\n                        \n                     (2016). Accessed 16 Aug 2016"},{"issue":"2","key":"903_CR24","first-page":"137","volume":"9","author":"L Bobocea","year":"2016","unstructured":"Bobocea, L., Spiridon, S., Petrescu, L., Gheorghe, C.M., Purcarea, V.L.: The management of external marketing communication instruments in health care services. J. Med. Life 9(2), 137\u2013140 (2016)","journal-title":"J. Med. Life"},{"key":"903_CR25","unstructured":"Health Insurance Institute of Slovenia: [Annual report of the Health Insurance Institute of Slovenia for 2014] Poslovno poro\u010dilo Zavoda za zdravstveno zavarovanje Slovenije za leto 2014 [In Slovenian]. \n                        http:\/\/www.zzzs.si\/ZZZS\/info\/egradiva.nsf\/o\/9B52139ED62405F7C1257DFD00573AF8?OpenDocument\n                        \n                     (2015). Accessed 4 Feb 2016"},{"key":"903_CR26","unstructured":"National Institute of Public Health: Medicine use in an ambulatory healthcare in 2014 [in Slovenian]. \n                        http:\/\/www.nijz.si\/sites\/www.nijz.si\/files\/datoteke\/poraba_ambulantno_predpisanih_zdravil_v_sloveniji_2014.pdf\n                        \n                     (2015). Accessed 5 Mar 2017"},{"key":"903_CR27","unstructured":"Brekke, K.R., Canta, C., Straume, O.R.: Reference pricing, generic entry, and pharmaceutical prices. \n                        http:\/\/www.hec.unil.ch\/documents\/seminars\/iems\/1717.pdf.pdf\n                        \n                     (2005). Accessed 8 Mar 2017"},{"issue":"3\u20134","key":"903_CR28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5639\/gabij.2012.0103-4.028","volume":"1","author":"P Dylst","year":"2012","unstructured":"Dylst, P., Vulto, A., Simoens, S.: Reference pricing systems in Europe: characteristics and consequences. Generics Biosimilar Initiat. J. 1(3\u20134), 127\u2013131 (2012)","journal-title":"Generics Biosimilar Initiat. J."},{"key":"903_CR29","unstructured":"Third Slovenian Meeting on Clinical Pharmacology: The safe use of medicines\u2014introduction of therapeutic reference pricing. \n                        http:\/\/ktf.si\/dogodki\/3-slovensko-srecanje-o-klinicni-farmakologiji-varna-uporaba-zdravil\/\n                        \n                     (2015). Accessed 21 Oct 2016"},{"issue":"2","key":"903_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40271-013-0042-z","volume":"7","author":"S Dunne","year":"2014","unstructured":"Dunne, S., Shannon, B., Dunne, C., Cullen, W.: Patient perceptions of generic medicines: a mixed-methods study. Patient 7(2), 177\u2013185 (2014). doi:\n                        10.1007\/s40271-013-0042-z","journal-title":"Patient"},{"issue":"10","key":"903_CR31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.5414\/CPP43472","volume":"43","author":"W Himmel","year":"2005","unstructured":"Himmel, W., Simmenroth-Nayda, A., Niebling, W., Ledig, T., Jansen, R.D., Kochen, M.M., Gleiter, C.H., Hummers-Pradier, E.: What do primary care patients think about generic drugs? Int. J. Clin. Pharmacol. Ther. 43(10), 472\u2013479 (2005)","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"903_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.healthpol.2011.10.001","volume":"104","author":"C Quintal","year":"2012","unstructured":"Quintal, C., Mendes, P.: Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy 104(1), 61\u201368 (2012). doi:\n                        10.1016\/j.healthpol.2011.10.001","journal-title":"Health Policy"},{"issue":"5","key":"903_CR33","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s11096-016-0370-x","volume":"38","author":"N Mardetko","year":"2016","unstructured":"Mardetko, N., Kos, M.: Patients\u2019 knowledge and attitude towards therapeutic reference pricing system in Slovenia. Int. J. Clin. Pharm. 38(5), 1301\u20131310 (2016). doi:\n                        10.1007\/s11096-016-0370-x","journal-title":"Int. J. Clin. Pharm."},{"key":"903_CR34","unstructured":"Business News Daily: What is a BCG matrix? \n                        http:\/\/www.businessnewsdaily.com\/5693-bcg-matrix.html\n                        \n                     (2016). Accessed 26 Nov 2016"},{"issue":"3","key":"903_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10198-009-0172-3","volume":"11","author":"T Stargardt","year":"2010","unstructured":"Stargardt, T.: The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur. J. Health Econ. 11(3), 267\u2013277 (2010). doi:\n                        10.1007\/s10198-009-0172-3","journal-title":"Eur. J. Health Econ."},{"key":"903_CR36","unstructured":"Duel between the marketing authorisation holders and Health Insurance Institute of Slovenia. \n                        http:\/\/www.delo.si\/zgodbe\/ozadja\/dvoboj-med-proizvajalci-zdravil-in-zzzs.html\n                        \n                     (2014). Accessed 20 Nov 2016"},{"key":"903_CR37","unstructured":"Worries about that the mortality would be higher due to therapeutic reference pricing [in Slovenian]. \n                        http:\/\/www.zurnal24.si\/skrbi-jih-da-bo-umrljivost-bolnikov-visja-terapevtske-skupine-zdravil-hipertenzija-clanek-241455\n                        \n                     (2014). Accessed 26 Nov 2016"},{"key":"903_CR38","unstructured":"Health Insurance Institute of Slovenia: The national health claims database. \n                        https:\/\/partner.zzzs.si\/wps\/portal\/portali\/aizv\/zdravila_in_zivila_za_posebne_zdravstvene_namene\/podatki_o_porabi_zdravil\/!ut\/p\/z0\/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTQxdPd2N_Q08LSyCDQ0cjZzMzXz8XQ0sTAz0C7IdFQGdnpEx\/\n                        \n                     (2016). Accessed 8 Mar 2017"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-017-0903-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-017-0903-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-017-0903-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T14:01:15Z","timestamp":1524492075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-017-0903-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,27]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1007\/s10198-017-0903-9","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,27]]}}}